7thANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE:

An Intensive Course on Translating Research into Drugs


Presented by the Alzheimer's Drug Discovery Foundation

February 10-12, 2013  ●  San Francisco, CA









The Drug Discovery for Neurodegeneration conference advances drug discovery for neurodegenerative diseases by educating scientists on the process of translating basic research into novel therapies.

The course is designed to give participants knowledge and relevant resources about this field of scientific investigation and address the associated barriers and challenges.

The program will focus on Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis.


COURSE OBJECTIVES

1.
 

 Train a cadre of interdisciplinary scientists in the principles of drug discovery for neurodegenerative disease

2.

 Provide a platform to exchange ideas, knowledge and resources about drug discovery for neurodegenerative disease

3.

 Stimulate pre-clinical research in the discovery and testing of novel compounds aimed at the prevention and treatment of neurodegenerative disease

4.

 Build public-private partnerships that will accelerate drug discovery for neurodegenerative disease.
WHAT YOU WILL LEARN

1.

 Challenges and opportunities in academic drug discovery
2. Fundamentals of medicinal chemistry relevant to drug discovery for neurodegenerative diseases
3. Newest trends in assay development and high throughput screening (HTS)
4. Go-no-go criteria for preclinical development, including pharmacokinetic behavior of candidate compounds, aqueous solubility, blood-brain barrier permeability, preliminary safety, and manufacturing issues
5. Study design considerations for animal model experiments
6. Biologics for challenging CNS targets and strategies to optimize brain delivery
7. Requirements for an Investigational New Drug (IND) application
8. Commercialization strategies for developing science into products
9. Best practices for working with tech transfer offices, managing intellectual property, and the role of funding organizations
10.

Funding & resources for preclinical therapeutics development for neurological disorders
SCIENTIFIC ADVISORY COMMITTEE

Kelly Bales, PhD, Pfizer Inc.

Kuldip Dave, PhD, Michael J. Fox Foundation for Parkinson’s Research

Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation

Marcie Glicksman, PhD, Harvard Medical School

Frank Longo, MD, Stanford University

Suzana Petanceska, PhD, National Institute on Aging

Rajesh Ranganathan, PhD, National Institute of Neurological Disorders

Diana Shineman, PhD, Alzheimer’s Drug Discovery Foundation

Edward G. Spack, PhD, Fast Forward, LLC

D. Martin Watterson, PhD, Northwestern University

TARGET AUDIENCE

Academic and industry scientists engaged in drug discovery research for neurodegenerative disease or CNS

Business development and licensing professionals

Alliance management professionals

Young investigators and graduate students
ARCHIVED PROGRAMS

All pages will open in new windows:
NEW 2013 Agenda, Biographies, Abstracts and Session Videorecordings

(you can also review all videocasts from this link.)

2012 Agenda and Webcast

review report published in Expert Opinion in Drug Discovery

2011 Agenda and Webcast

2010 Agenda and Webcast

2009 Agenda

2008 Agenda

2007 Agenda

 
 
The Drug Discovery for Neurodegeneration conference is presented by the Alzheimer's Drug Discovery Foundation (ADDF), the only public charity solely dedicated to rapidly accelerating the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging.